10-K: Avinger Inc. Files 10-K Report, Details Financials and Strategic Moves

Avinger Inc.'s 10-K filing reveals a challenging financial year with strategic moves including a new partnership and financing.

Summary

• Avinger Inc. reported a net loss of $18.3 million in 2023 and $17.6 million in 2022, with an accumulated deficit of $420.7 million as of December 31, 2023.
• The company's revenue decreased to $7.7 million in 2023 from $8.3 million in 2022, primarily due to staffing shortages and resource constraints at customer facilities.
• Avinger is developing new CTO crossing devices for both peripheral and coronary markets, which will require additional expenses.
• The company has a significant amount of debt, with $14.3 million outstanding under a loan agreement with CRG as of December 31, 2023.
• Avinger entered into a strategic collaboration with Zylox-Tonbridge, including a $7.5 million investment and a licensing agreement for the Greater China region.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• Avinger is working to regain compliance with Nasdaq listing requirements, including a minimum stockholders equity requirement.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation for Avinger, with declining revenues, increasing losses, and substantial debt. While there are some positive developments, such as the strategic partnership with Zylox-Tonbridge, the overall sentiment is negative due to the company's financial instability and the auditor's going concern warning.

Positives

• Avinger has entered into a strategic collaboration with Zylox-Tonbridge, which includes a $7.5 million investment and a licensing agreement for the Greater China region.
• The company is developing new products for the coronary artery disease market, which could expand its revenue base.
• Avinger has received FDA clearance for new products, including Tigereye ST and Pantheris LV.
• The company has extended its lease agreement for its facilities through November 2025.

Negatives

• Avinger has a history of net losses and may not be able to achieve or sustain profitability.
• The company has a significant amount of debt, which may adversely affect its ability to operate its business.
• Avinger's revenue declined in 2023, primarily due to staffing shortages and resource constraints at customer facilities.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• Avinger is facing challenges in maintaining compliance with Nasdaq listing requirements.
• The company relies on a limited number of products with a limited commercial history.

Risks

• Avinger may not be able to secure additional financing on favorable terms, or at all, to meet its future capital needs.
• The company's ability to generate sufficient cash to service its debt obligations is uncertain.
• Covenants under the Loan Agreement with CRG will restrict Avinger's business in many ways.
• The company's success depends on a limited number of products, particularly the Pantheris product family, all of which have a limited commercial history.
• Avinger relies heavily on its sales professionals to market and sell its products, and the loss of key employees could harm its business.
• The company faces intense competition from companies with greater resources and more established products.
• Disruptions in the supply chain could have a material adverse effect on Avinger's operating and financial results.
• The company's technology infrastructure is vulnerable to cybersecurity incidents and data breaches.
• Avinger may be subject to intellectual property litigation or administrative proceedings.
• The company's ability to market its current products in the United States is limited to use in peripheral vessels.
• Changes in coverage and reimbursement for procedures using Avinger's products could affect their adoption and the company's future revenues.
• The company's stock price may be volatile, and purchasers of its common stock could incur substantial losses.
• Nasdaq may delist Avinger's securities from its exchange, which could harm its business and limit its stockholders' liquidity.

Future Outlook

Avinger expects its revenues to increase in 2024 due to the introduction of new products, investments in sales personnel, and easing conditions involving hospital staffing and capacity issues. The company also anticipates needing additional capital to finance its operations and product development.

Management Comments

• The company believes that its cash and cash equivalents at December 31, 2023, together with the aforementioned financing, debt and other financing activities and expected revenues from operations, will be sufficient to satisfy its capital requirements and fund its operations through the second quarter of 2024.
• The company is taking definitive steps pursuant to its plan as presented to the Panel to ensure its compliance with the Equity Rule and all other applicable criteria for continued listing on Nasdaq.

Industry Context

The medical device industry is highly competitive, with rapid technological development and product innovation. Avinger competes with a variety of products for the treatment of PAD, including other CTO crossing devices, stents, balloons, and atherectomy catheters. Many of Avinger's competitors have substantially greater financial, manufacturing, marketing, and technical resources.

Comparison to Industry Standards

• Avinger's financial performance is weaker than many of its competitors in the medical device industry, particularly those with more established products and greater resources.
• The company's reliance on a limited number of products and its history of net losses are not typical of more mature medical device companies.
• Avinger's gross margin of 26% in 2023 is lower than the industry average for medical device companies.
• The company's debt levels are high compared to many of its peers, which could limit its financial flexibility.
• Avinger's cash burn rate is high, and it will need to raise additional capital to continue its operations.

Related Party Transactions

• The company has entered into various transactions with CRG, including a loan agreement, a securities purchase agreement, and amendments to these agreements.
• The company has entered into a strategic collaboration with Zylox-Tonbridge, including a licensing agreement, a collaboration agreement, and a securities purchase agreement.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential losses due to the company's need for additional financing.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may be concerned about the company's ability to continue providing products and services.
• Creditors face the risk of non-payment or delayed payment due to the company's high debt levels.

Next Steps

• Avinger will continue to develop new products for the coronary artery disease market.
• The company will work to expand its sales and marketing infrastructure.
• Avinger will seek additional regulatory clearances from the FDA for its products.
• The company will attempt to regain compliance with Nasdaq listing requirements.
• Avinger will continue to monitor and address supply chain issues.

Key Dates

Keywords

Avinger, Lumivascular, peripheral artery disease, atherectomy, CTO crossing, medical devices, financial results, strategic collaboration, debt financing, Nasdaq, regulatory approvals, clinical trials